Can outcomes from clinical trials be directly applied to patients seen in everyday practice?
In this EMUC TV interview, Assoc. Prof. Carlotta Palumbo speaks with Dr. Luca Lambertini about a large international analysis of patients with clear cell renal cell carcinoma (ccRCC) eligible for adjuvant pembrolizumab. Using data from the YAU RCC Registry, the study compared real-world patients with those enrolled in the placebo arm of the landmark KEYNOTE-564 trial and identified important differences in patient characteristics and disease-free survival outcomes. The discussion highlights the value of real-world evidence in refining patient selection and helping clinicians translate clinical trial data into daily practice.